4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) Revenue
Annual & quarterly revenue history · segment & region breakdown
FDMT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 months4D Molecular Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.09B, an increase of 230194.59% year-over-year from $0.09B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.09B | +$0.09B | +230194.59% |
| 2024-12-31 | $0.00B | -$0.02B | -99.82% |
| 2023-12-31 | $0.02B | +$0.02B | +562.29% |
| 2022-12-31 | $0.00B | -$0.01B | -82.65% |
| 2021-12-31 | $0.02B | +$0.00B | +32.52% |
| 2020-12-31 | $0.01B | +$0.01B | +94.85% |
| 2019-12-31 | $0.01B | -$0.01B | -50.56% |
| 2018-12-31 | $0.01B | +$0.01B | +144.04% |
| 2017-12-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare FDMT revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income 4D Molecular Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
4D Molecular Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from 4D Molecular Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FDMT revenue · 4 questionsFDMT's trailing twelve-month (TTM) revenue is $0.09B. That is an increase of 230194.59% year-over-year from $0.09B in FY2025.
▸ Source: FMP · 4D Molecular Therapeutics, Inc. SEC filings · GAAP · 4D Molecular Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026